GTBP’s platform is designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells. In plain English, the company is working on a more targeted immune system approach at a time when the broader cancer treatment category continues to expand aggressively.
And after reviewing the latest company materials, market data, and today’s
fresh clinical update, we have GTBP on Thursday’s radar for several key reasons: first patient dosed in a Phase 1 solid tumor trial, recent GTB 3650 safety progress, multiple pipeline shots, a stated cash runway into Q4 2026, and a float listed around 30.83M shares.
Now let’s get into it.
GTBP Company Website
Yesterday’s Fresh Hook: GTB 5550 Is Now Dosing
The biggest update is the newest one.
GT Biopharma announced on May 14, 2026 that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB 5550, its B7 H3
targeted natural killer cell engager for solid tumors expressing B7 H3.
That changes the setup in a meaningful way.
This is no longer just a cleared to proceed story. GTB 5550 is now dosing patients.
Company materials also state that GTB 5550 is now the third TriKE® to enter the clinic, while expanding the platform into a broader solid tumor setting.
The company said it anticipates providing updates in the second half of 2026 as enrollment progresses through dose escalation cohorts.
That is the kind of timeline shift that can wake up a quiet biotech name fast.
The Bigger Setup
What makes GTBP interesting is not just that it sits inside a large oncology category. Plenty of small biotech names can say
that.
The sharper angle here is that GT Biopharma is building around NK cell engagers, a therapeutic approach designed to activate natural killer cells and direct them toward specific cancer cells.
Natural killer cells are cytotoxic lymphocytes in the innate immune system. They can recognize and kill cancer cells and help mediate antibody dependent cellular cytotoxicity through the CD16 activating
receptor.
GTBP’s TriKE® platform is designed to bridge NK cells to tumor cells while inducing NK cell activation and expansion at the site of the tumor to enhance killing.
That is the core platform story.
The company is not simply trying to create another oncology asset in a crowded field. It is developing a modular NK cell engager platform that company materials describe as
capable of being applied to known or proprietary tumor targets and other target areas, including HIV reservoirs. Several candidates are either in research development or planned.
Why This Platform Story Matters
This is where the story starts getting more interesting.
Our research shows GT Biopharma is now focused on its second generation TriKE®
platform, which company materials describe as 10 to 40 times more potent than first generation TriKE®.
That shift matters because GTBP’s earlier GTB 3550 program helped establish clinical proof of concept in a completed Phase 1 study for relapsed or refractory AML and high risk MDS, where the candidate was shown to be safe and well tolerated.
GTB 3550 has since been
supplanted by the second generation GTB 3650 program after stronger data suggested the newer approach was more potent and showed better preclinical anti tumor activity using camelid nanobody technology and wild type IL 15.
That gives the current GTBP setup a cleaner development arc: first generation clinical experience, followed by a second generation platform designed to be stronger.
The Lead Blood Cancer
Track
The lead clinical story before today’s GTB 5550 update has been GTB 3650, the company’s first second generation camelid nanobody TriKE® being tested clinically for CD33 positive leukemias, including AML and MDS.
Company materials show the GTB 3650 IND application was cleared and enrollment began on January 21, 2025. The ongoing Phase 1
dose escalation study is evaluating GTB 3650 in relapsed or refractory CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high risk myelodysplastic syndrome.
That clinical program recently gave GTBP another point to watch.
On October 23, 2025, GT Biopharma announced successful completion of the formal safety review for Cohort 3 at 5
ug/kg/day, with no safety or tolerability issues observed. That allowed the company to advance into Cohort 4 at 10 ug/kg/day.
For early stage biotech, that is a meaningful checkpoint. It does not guarantee where the program goes next. But safety progress is one of the gates these stories need to pass before the market starts focusing more closely on higher dose levels, biomarker signals, and early
activity.
The company also stated that Cohort 4 may be more reflective of the potential clinical efficacy threshold, based on positive trends in multiple immunological biomarkers from the first six patients in Cohorts 1 through 3, the absence of dose limiting toxicities, and the lower dose levels used so far.
Company materials show Cohort 4 enrollment is ongoing, and GT Biopharma expects to
initiate dosing in Cohort 5 at 25 ug/kg/day in Q2 2026. Dose escalation may continue up to Cohort 7 if necessary, with the potential to evaluate GTB 3650 in a total of 14 patients, meaning two patients per cohort.
The next GTB 3650 update is anticipated in the third quarter of 2026, and it is expected to include longer term follow up on the six patients from Cohorts 1 through 3, along with initial observations
from patients in Cohorts 4 and 5.
That gives this story another future data window to track.
The Solid Tumor Expansion
Now GTB 5550 has moved from expected trial start to first patient dosed.
That matters because GTB 5550 expands the TriKE® platform into solid tumors expressing B7 H3, a target the company says is broadly
expressed across many common and difficult to treat solid tumor cancers.
The Phase 1a dose escalation portion of the trial will focus primarily on enrolling prostate cancer patients and evaluate up to six dose levels to identify the maximum tolerated dose. After the dose escalation phase, the Phase 1b expansion component is designed to enroll patients with up to seven different tumor types: castration resistant
prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non small cell lung cancer, pancreatic cancer, and bladder cancer.
Company materials also note that this Phase 1 trial with GTB 5550 will be the first nanobody TriKE® tested with more patient friendly subcutaneous dosing.
That gives GTBP two active clinical storylines to watch: GTB 3650 in CD33 expressing hematologic malignancies and GTB 5550 in B7
H3 expressing solid tumors.
That is a stronger setup than a single asset story.
Why Prostate Cancer Is A Key Focus
The first patient dosed update also adds a more specific patient focus.
The company said the dose escalation phase is likely to focus on prostate cancer patients. Dr. Nicholas Zorko of the University of Minnesota
stated that patients with metastatic castration resistant prostate cancer have B7 H3 expressed in over 90% of tumors, and PSA can serve as an early biomarker of therapeutic activity.
That does not mean GTB 5550 will succeed. Early clinical work still has to prove safety, tolerability, dose behavior, and activity.
But it does give the market a more defined first clinical lane to watch as the trial
begins dosing.
More Than One Shot On Goal
GTBP also has another pipeline piece in GTB 7550, which is in development for CD19 positive lymphoid malignancies and autoimmune disease.
Our research shows GTB 7550 has been tested and published preclinically using models of lymphoma and chronic lymphocytic leukemia. Based on
early preclinical activity targeting normal B cells, studies are ongoing to develop GTB 7550 in autoimmune disease.
So the setup is not just one molecule, one trial, one narrow lane.
It is a platform story with multiple shots, which is exactly the kind of structure that can keep a smaller biotech name in the conversation when the broader category is active.
The Balance
Sheet And Float Setup
There is also the balance sheet detail.
When GT Biopharma announced the prior FDA clearance for GTB 5550, company materials cited an unaudited proforma cash balance of approximately $9M as of January 31, 2026, which was anticipated to extend cash runway through Q4 2026.
That does not remove financing risk,
because small biotech funding risk never magically disappears. But it gives readers a clearer view of the company’s stated runway as it heads through expected clinical activity in 2026.
Then there is the float.
Yahoo Finance data we reviewed lists GTBP with
roughly 30.83M shares in its float.
That is a key detail for this kind of audience. A lower float does not guarantee movement, but it can help create a more sensitive setup when attention increases. If a company update, sector move, or clinical timeline pulls new eyes onto the name, float structure can become part of the volatility equation quickly.
Why GTBP Is On Radar Now
And that is really why GTBP is worth watching now.
The immuno-oncology market is expanding. The company has an NK cell engager platform designed to improve targeted cancer cell killing. GTB 3650 has already moved through a Cohort 3 safety review with no safety or tolerability issues observed. GTB 5550 has now dosed the first patient in a Phase 1 solid tumor trial. GTB 7550 adds another preclinical pipeline angle in CD19
positive lymphoid malignancies and autoimmune disease. The company has stated cash runway expectations through Q4 2026. Yahoo Finance lists the float around 30.83M shares.
Put all of that together, and this is not just a random biotech company drifting through the screen.
It is a low float Nasdaq biotech with a platform story, fresh clinical movement, a major category backdrop, and a timeline that could keep attention
building through the second half of 2026.
Of course, biotech comes with risk. Clinical timelines can shift. Early data can disappoint. Funding needs can change. Nothing here is guaranteed.
But as far as radar setups go, GTBP has enough pieces in motion to deserve a serious look today.
GT Biopharma, Inc. (Nasdaq: GTBP) is officially in focus.
Keep
this one close. GTBP IR Page
To your success,
Max Masters
Co-founder, Market Tips Newsletter
